This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Swedish Orphan Biovitrum
Drug Names(s): Anakinra, IL-1ra, Antril
Description: Kineret (anakinra) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). Kineret blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. Kineret differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus. Because of its novel molecular mechanism of action, Kineret may be complementary to other classes of anti-inflammatories used against RA, such as COX-2 inhibitors, non-COX-2 related NSAIDS, other DMARDs, and TNF modulators like Enbrel and Remicade.
Deal Structure: Amgen acquired Kineret along with its acquisition of Synergen, Inc.
NPS and Amgen
NPS Pharmaceuticals executed an agreement with Amgen in August 2004 to promote Kineret for the treatment of moderate to severe rheumatoid arthritis in the United States. The agreement between NPS and Amgen calls for Amgen to supply product, materials and support to NPS. In return, NPS will promote Kineret and receive a percentage of incremental Kineret revenues. NPS will be the exclusive representative of the drug to rheumatologists.
In February 2006, NPS announced is has terminated its agreement with Amgen to promote Kineret starting March 30th, 2006. NPS had previously used Kineret to provide training for its sales staff and gain relationships with rheumatologists. With the upcoming Preos PDUFA, NPS no longer feels the promotion of Kineret is necessary and will concentrate is sales efforts on Restasis and Preos.
Biovitrum and Amgen
In September 2003, Amgen partnered with...See full deal structure in Biomedtracker
Partners: Amgen, Inc. Horizon Pharma plc
Additional information available to subscribers only: